Fresenius Kabi And Dr. Reddy's Announce FDA Approval Of Rituximab Biosimilar

Fresenius Kabi and Dr. Reddy's Laboratories have received FDA approval for their rituximab biosimilar, adding to several already approved alternatives to Genentech's RITUXAN in the U.S. market.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.